{"id":69520,"date":"2026-07-07T20:47:33","date_gmt":"2026-07-07T12:47:33","guid":{"rendered":"https:\/\/flcube.com\/?p=69520"},"modified":"2026-07-07T20:47:34","modified_gmt":"2026-07-07T12:47:34","slug":"serapha-bio-secures-2b-base-editing-therapy-deal-for-aatd-with-yoltech-and-completes-230m-merger","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69520","title":{"rendered":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Serapha Bio<\/strong> announced a transformative series of transactions including an <strong>exclusive worldwide license<\/strong> from <strong>YolTech Therapeutics<\/strong> for <strong>SERP-01<\/strong>, an <strong>in vivo base editing therapy<\/strong> for <strong>alpha-1 antitrypsin deficiency (AATD)<\/strong>, alongside a <strong>merger with Nasdaq-listed Boundless Bio<\/strong> and a <strong>$230 million financing round<\/strong>, positioning the combined entity for accelerated clinical development.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-framework\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>License Agreement<\/strong><\/td><td>Exclusive worldwide rights (excluding Greater China) for SERP-01 (YOLT-202)<\/td><\/tr><tr><td><strong>Upfront Consideration<\/strong><\/td><td>Cash payment + minority equity stake in Serapha to YolTech<\/td><\/tr><tr><td><strong>Milestone Potential<\/strong><\/td><td>Over <strong>USD 2 billion<\/strong> in regulatory and commercial milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales<\/td><\/tr><tr><td><strong>Merger Partner<\/strong><\/td><td>Nasdaq-listed Boundless Bio<\/td><\/tr><tr><td><strong>Combined Entity<\/strong><\/td><td>Serapha Bio, Inc. (Nasdaq ticker: &#8220;AATD&#8221;)<\/td><\/tr><tr><td><strong>Concurrent Financing<\/strong><\/td><td>USD 230 million co-led by RA Capital Management and RTW Investments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-serp-01-base-editing-therapy\" class=\"wp-block-heading\">Asset Profile: SERP-01 Base Editing Therapy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> <strong>Alpha-1 antitrypsin deficiency (AATD)<\/strong> \u2013 rare genetic disorder causing lung and liver disease<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Built on YolTech&#8217;s proprietary <strong>next-generation adenine base editor (YolBE)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Achieves <strong>precise gene repair<\/strong> at the <strong>SERPINA1 PiZ locus<\/strong> by correcting the high-risk <strong>PiZ mutation<\/strong> to normal <strong>PiM<\/strong><\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> <strong>Minimal bystander editing<\/strong> \u2013 almost completely avoids unintended modifications of surrounding bases<\/li>\n\n\n\n<li><strong>Therapeutic Paradigm:<\/strong> <strong>&#8220;One-and-done&#8221; curative approach<\/strong> addressing root genetic cause rather than symptomatic management<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> FDA IND approval granted March 2026 for direct Phase II\/III initiation; investigator-initiated trial ongoing at Shanghai Renji Hospital<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-milestones-amp-clinical-strategy\" class=\"wp-block-heading\">Regulatory Milestones &amp; Clinical Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Jurisdiction<\/th><th>Status<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>FDA Orphan Drug Designation granted; IND approved March 2026<\/td><td>Enables direct Phase II\/III studies; seven-year market exclusivity potential<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Investigator-initiated trial (IIT) commenced at Shanghai Renji Hospital<\/td><td>Parallel development pathway supporting global registration strategy<\/td><\/tr><tr><td><strong>Global<\/strong><\/td><td>Worldwide license excludes only Greater China<\/td><td>Comprehensive commercial rights for major pharmaceutical markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-investment-thesis\" class=\"wp-block-heading\">Strategic Rationale &amp; Investment Thesis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Serapha Bio<\/strong><\/td><td>Immediate access to late-stage gene editing asset with clear regulatory pathway; substantial capital runway for pivotal trials; public listing provides liquidity and visibility<\/td><\/tr><tr><td><strong>YolTech Therapeutics<\/strong><\/td><td>Significant upfront value realization while retaining Greater China rights; milestone structure aligns with clinical success; equity participation in well-capitalized public entity<\/td><\/tr><tr><td><strong>Investor Consortium<\/strong><\/td><td>Access to potentially curative gene editing therapy for validated orphan indication; experienced management team; clear path to market with established regulatory precedents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The AATD market represents a high-value orphan disease opportunity with approximately 200,000 diagnosed patients globally and limited treatment options beyond augmentation therapy and organ transplantation.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-technological-differentiation\" class=\"wp-block-heading\">Competitive Landscape &amp; Technological Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current AATD Treatments:<\/strong> Weekly intravenous augmentation therapy (lifetime cost: $100,000+\/year) or liver\/lung transplantation<\/li>\n\n\n\n<li><strong>Gene Therapy Competition:<\/strong> Several AAV-based approaches in development but face challenges with immunogenicity and durability<\/li>\n\n\n\n<li><strong>Base Editing Advantage:<\/strong> Precise correction without double-strand DNA breaks potentially offers superior safety profile compared to CRISPR-Cas9 nuclease approaches<\/li>\n\n\n\n<li><strong>Bystander Editing Minimization:<\/strong> YolBE platform&#8217;s specificity addresses key safety concern that has limited previous base editing applications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Serapha-YolTech transactions, clinical development plans, regulatory milestones, and commercial prospects for SERP-01. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and market dynamics in the gene editing therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[24,4841,1168],"class_list":["post-69520","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-rare-orphan-disease-drugs","tag-serapha-bio","tag-yoltech-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69520\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger\" \/>\n<meta property=\"og:description\" content=\"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69520\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T12:47:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T12:47:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger\",\"datePublished\":\"2026-07-07T12:47:33+00:00\",\"dateModified\":\"2026-07-07T12:47:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520\"},\"wordCount\":514,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"Serapha Bio\",\"YolTech Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69520#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69520\",\"name\":\"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T12:47:33+00:00\",\"dateModified\":\"2026-07-07T12:47:34+00:00\",\"description\":\"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69520\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69520#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger - Insight, China&#039;s Pharmaceutical Industry","description":"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69520","og_locale":"en_US","og_type":"article","og_title":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger","og_description":"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.","og_url":"https:\/\/flcube.com\/?p=69520","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T12:47:33+00:00","article_modified_time":"2026-07-07T12:47:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69520#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69520"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger","datePublished":"2026-07-07T12:47:33+00:00","dateModified":"2026-07-07T12:47:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69520"},"wordCount":514,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Rare \/ orphan disease drugs","Serapha Bio","YolTech Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69520#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69520","url":"https:\/\/flcube.com\/?p=69520","name":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T12:47:33+00:00","dateModified":"2026-07-07T12:47:34+00:00","description":"Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech Therapeutics for SERP-01, an in vivo base editing therapy for alpha-1 antitrypsin deficiency (AATD), alongside a merger with Nasdaq-listed Boundless Bio and a $230 million financing round, positioning the combined entity for accelerated clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69520#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69520"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69520#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69520"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69520\/revisions"}],"predecessor-version":[{"id":69523,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69520\/revisions\/69523"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}